Free Trial

Maven Securities LTD Takes Position in Guardian Pharmacy Services, Inc. (NYSE:GRDN)

Guardian Pharmacy Services logo

Maven Securities LTD bought a new stake in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 180,543 shares of the company's stock, valued at approximately $3,033,000. Maven Securities LTD owned 0.29% of Guardian Pharmacy Services as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Stephens Inc. AR acquired a new position in shares of Guardian Pharmacy Services during the 3rd quarter valued at $189,000. Royce & Associates LP purchased a new stake in shares of Guardian Pharmacy Services in the third quarter valued at about $1,260,000. Foundry Partners LLC purchased a new stake in Guardian Pharmacy Services during the third quarter worth about $1,680,000. Seven Grand Managers LLC purchased a new stake in Guardian Pharmacy Services during the third quarter worth about $2,515,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Guardian Pharmacy Services during the third quarter worth about $5,460,000.

Guardian Pharmacy Services Trading Down 0.8 %

Shares of GRDN stock traded down $0.20 during mid-day trading on Wednesday, reaching $24.77. 254,963 shares of the company's stock traded hands, compared to its average volume of 155,530. Guardian Pharmacy Services, Inc. has a 12 month low of $14.16 and a 12 month high of $25.57. The firm's 50-day simple moving average is $19.74.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($2.19). The company had revenue of $314.39 million for the quarter, compared to the consensus estimate of $303.21 million. On average, sell-side analysts forecast that Guardian Pharmacy Services, Inc. will post 0.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardian Pharmacy Services

In related news, Director Thomas J. Salentine, Jr. acquired 35,714 shares of the business's stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $14.00 per share, with a total value of $499,996.00. Following the acquisition, the director now directly owns 35,714 shares in the company, valued at $499,996. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Steven D. Cosler acquired 7,000 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were bought at an average cost of $21.22 per share, with a total value of $148,540.00. Following the completion of the acquisition, the director now owns 17,713 shares in the company, valued at approximately $375,869.86. This represents a 65.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on GRDN shares. Raymond James initiated coverage on shares of Guardian Pharmacy Services in a research note on Monday, October 21st. They issued an "outperform" rating and a $21.00 target price for the company. Truist Financial lifted their target price on shares of Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Finally, Stephens assumed coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, October 22nd. They issued an "overweight" rating and a $21.00 target price on the stock.

Read Our Latest Stock Analysis on GRDN

Guardian Pharmacy Services Profile

(Free Report)

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.

Featured Stories

Institutional Ownership by Quarter for Guardian Pharmacy Services (NYSE:GRDN)

Should you invest $1,000 in Guardian Pharmacy Services right now?

Before you consider Guardian Pharmacy Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.

While Guardian Pharmacy Services currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Why Meta Is Still a Top Stock Pick for 2025

Why Meta Is Still a Top Stock Pick for 2025

Meta Platforms continues to shine as one of the strongest AI-driven companies heading into 2025. Learn why Meta is a solid pick for next year.

Related Videos

Meta Platforms Tops Most Upgraded Stocks List—Here’s What to Expect
Alphabet Gaining Momentum: Can It Reach $200 by December?
3 Momentum Stock Picks With Room to Run

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines